Literature DB >> 29302767

Oxford House Residents' Attitudes Toward Medication Assisted Treatment Use in Fellow Residents.

John M Majer1, Christopher Beasley2,3, Emily Stecker2, Ted J Bobak4, Joshua Norris4, Hai Minh Nguyen4, Maisie Ogata4, Jordana Siegel4, Elzbieta Wiedbusch4, Isabel Dovale, Noah Gelfman, Sarah Callahan, Leonard A Jason4.   

Abstract

Methadone and buprenorphine/naloxone are medication assisted treatment (MAT) options for treating opioid use disorder, yet attitudes regarding their use within abstinence-based recovery homes have not been assessed. The present investigation examined attitudes regarding MAT utilization among residents living in Oxford Houses. This cross-sectional investigation compared residents (n = 87) receiving MAT whose recent drug use involved opioids, and two groups not receiving MATs; those who had used opioids and those who had used substances other than opioids. The vast majority of residents were not receiving MAT, yet 32% reported MAT histories. Negative attitudes regarding MAT were observed among residents who were not receiving MAT. Those presently receiving MAT reported mixed attitudes regarding the use of methadone and buprenorphine/naloxone, and two of these residents reported they had never been prescribed MAT. Findings suggest that abstinence-based recovery homes such as Oxford Houses may not be optimal resources for persons receiving MATs.

Entities:  

Keywords:  Abstinence-based recovery homes; Buprenorphine/naloxone; Medication assisted treatment; Methadone; Oxford House; Suboxone

Mesh:

Substances:

Year:  2018        PMID: 29302767     DOI: 10.1007/s10597-017-0218-4

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  15 in total

Review 1.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

2.  Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.

Authors:  Björn Johnson; Torkel Richert
Journal:  Int J Drug Policy       Date:  2014-10-30

3.  Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.

Authors:  S Mercadante; M Sapio; R Serretta; M Caligara
Journal:  Ann Oncol       Date:  1996-08       Impact factor: 32.976

4.  Heroin addiction--a metabolic disease.

Authors:  V P Dole; M E Nyswander
Journal:  Arch Intern Med       Date:  1967-07

5.  12-Step involvement among a U.S. national sample of Oxford House residents.

Authors:  John M Majer; Leonard A Jason; Joseph R Ferrari; Steve A Miller
Journal:  J Subst Abuse Treat       Date:  2011-02-24

Review 6.  Implications of methadone maintenance for theories of narcotic addiction.

Authors:  V P Dole
Journal:  JAMA       Date:  1988-11-25       Impact factor: 56.272

Review 7.  Buprenorphine for the management of opioid withdrawal.

Authors:  L Gowing; R Ali; J White
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

8.  The need for substance abuse after-care: longitudinal analysis of Oxford House.

Authors:  Leonard A Jason; Margaret I Davis; Joseph R Ferrari
Journal:  Addict Behav       Date:  2006-07-14       Impact factor: 3.913

9.  Facilitating medical withdrawal from opiates in rural Ontario.

Authors:  N Kiepek; L Hancock; D Toppozini; H Cromarty; A Morgan; L Kelly
Journal:  Rural Remote Health       Date:  2012-10-23       Impact factor: 1.759

10.  Social support and self-efficacy for abstinence: is peer identification an issue?

Authors:  John M Majer; Leonard A Jason; Joseph R Ferrari; Leon B Venable; Bradley D Olson
Journal:  J Subst Abuse Treat       Date:  2002-10
View more
  4 in total

1.  Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.

Authors:  Andrew S Huhn; J Gregory Hobelmann; Justin C Strickland; George A Oyler; Cecilia L Bergeria; Annie Umbricht; Kelly E Dunn
Journal:  JAMA Netw Open       Date:  2020-02-05

2.  Association of facility characteristics and substance use disorder outcomes at discharge from residential treatment.

Authors:  Jennifer Miles; Amy Mericle; Grant Ritter; Sharon Reif
Journal:  J Subst Abuse Treat       Date:  2021-11-15

3.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

4.  Medication assisted therapy and recovery homes.

Authors:  Leonard A Jason; John M Majer; Ted J Bobak; Jack O'Brien
Journal:  J Prev Interv Community       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.